Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00134199 · ClinicalTrials.gov registry record · Phase 2
A Study Of 6-Month Duration To Evaluate The Weight Loss Effect Of Various Doses Of CP-945,598 In Obese Subjects
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 282
- Enrollment target
NCT00134199 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 282 participants.
The verdict
NCT00134199, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 282 participants
- Enrollment target
Study Summary
To evaluate the effect of 6-month administration of CP-945,598 on: * weight loss and waist circumference, * blood pressure, cholesterol, glucose * other biochemical variables like insulin, leptin, ghrelin, adiponectin, PAI 1, TNF-α and hsCRP * the relationship between the concentration of the drug on the blood and the above parameters * physical and psychosocial functioning, weight related symptoms, treatment satisfaction, appetite/hunger/satiety/craving and mood, anxiety, anhedonia and depression
Interventions
- DRUG CP-945,598
- DRUG sibutramine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 282 participants |
| Start Date | 2005-03 |
| Est. Completion | 2005-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00134199
The ClinicalTrials.gov registry entry for NCT00134199 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 282 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CP-945,598 is the first listed.
NCT00134199 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00134199 about?
NCT00134199 is a clinical study titled "A Study Of 6-Month Duration To Evaluate The Weight Loss Effect Of Various Doses Of CP-945,598 In Obese Subjects". To evaluate the effect of 6-month administration of CP-945,598 on: * weight loss and waist circumference, * blood pressure, cholesterol, glucose * other biochemical variables like insulin, leptin, ghrelin, adiponectin, PAI 1, TNF-α and hsCRP * the relationship between the concentration of the drug...
What is the current status of trial NCT00134199?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 282 participants. The study started on 2005-03. Estimated completion is 2005-11.
What interventions are being tested in trial NCT00134199?
The interventions under investigation include: CP-945,598 (DRUG), sibutramine (DRUG).
Who is sponsoring clinical trial NCT00134199?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.